Evidence map›Paper›PMID 33014973›Full record

Observational studyFrontiers in public health2020

Characteristic of 523 COVID-19 in Henan Province and a Death Prediction Model.

Xiaoxu Ma, Ang Li, Mengfan Jiao, Qingmiao Shi, Xiaocai An, Yonghai Feng, Lihua Xing, Hongxia Liang, Jiajun Chen, Huiling Li and 13 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Frontiers in public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 7 pooled it
0.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 7 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Data mining approach to predicting of death in patients with COVID-19.Journal of education and health promotion · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cardiovascular markers and COVID-19.Materials today. Proceedings · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

Xiaoxu MaDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ang LiDepartment of Henan Gene Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mengfan JiaoDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qingmiao ShiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaocai AnDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yonghai FengDepartment of Respiration, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lihua XingDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Hongxia LiangDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiajun ChenDepartment of Medical Services, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Huiling LiDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Juan LiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zhigang RenDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ranran SunDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Guangying CuiDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yongjian ZhouDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ming ChengDepartment of Medical Information, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pengfei JiaoDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yu WangDepartment of Henan Gene Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiyuan XingDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shen ShenDepartment of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qingxian ZhangDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Aiguo XuDepartment of Respiration, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zujiang YuDepartment of Henan Gene Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNFifth Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Certain high-risk factors related to the death of COVID-19 have been reported, however, there were few studies on a death prediction model. This study was conducted to delineate the clinical characteristics of patients with coronavirus disease 2019 (covid-19) of different degree and establish a death prediction model. In this multi-centered, retrospective, observational study, we enrolled 523 COVID-19 cases discharged before February 20, 2020 in Henan Province, China, compared clinical data, screened for high-risk fatal factors, built a death prediction model and validated the model in 429 mild cases, six fatal cases discharged after February 16, 2020 from Henan and 14 cases from Wuhan. Out of the 523 cases, 429 were mild, 78 severe survivors, 16 non-survivors. The non-survivors with median age 71 were older and had more comorbidities than the mild and severe survivors. Non-survivors had a relatively delay in hospitalization, with higher white blood cell count, neutrophil percentage, D-dimer, LDH, BNP, and PCT levels and lower proportion of eosinophils, lymphocytes and albumin. Discriminative models were constructed by using random forest with 16 non-survivors and 78 severe survivors. Age was the leading risk factors for poor prognosis, with AUC of 0.907 (95% CI 0.831-0.983). Mixed model constructed with combination of age, demographics, symptoms, and laboratory findings at admission had better performance (

Indexed as

COVID-19AgedChinaHumansRetrospective StudiesRisk FactorsSARS-CoV-2death prediction modelepidemiology investigationnovel coronavirus pneumoniarandom forestrisk factors

Identifiers

PMID33014973
PMCPMC7506160
OpenAlexW3083854065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.